Modular Medical Secures IRB Approval for Pivot Insulin Pump Study

Reuters
11/17
Modular Medical Secures IRB Approval for Pivot Insulin Pump Study

Modular Medical Inc. has received Institutional Review Board (IRB) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system. The study will deliver insulin to adult participants with diabetes wearing continuous glucose monitors, aiming to simulate real-world conditions and gather data on device function, usability, and participant feedback. This IRB approval is a key milestone as the company awaits FDA clearance for the Pivot system, which has not yet been cleared for sale. No grant or funding from multiple organizations was mentioned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102920) on November 17, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10